reports
Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til dir...
Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til direktion og ledende medarbejdere ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): I henhold til selskabets vederlagspolitik, som er vedtaget på selskabets ordinære generalforsamling den 16. marts 2026, og i tråd med selskabets sædvanlige praksis har bestyrelsen truffet beslutning om at tildele indtil i alt 145.000 aktiebaserede instrumenter i overensstemmelse med selskabets langsigtede incitamentsprogram (LTIP) for direktion og en kreds af ledende medarbejdere for 2026. Formålet med LTIP er at tilskynde og belønne langsigtet vær...
Grant of share-based long-term incentive instruments to members of the...
Grant of share-based long-term incentive instruments to members of the Board of Management and key employees ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): According to the company’s remuneration policy adopted at the company's Annual General Meeting on 16 March 2026 and in line with the company’s usual practice, the Board of Directors has passed a resolution to grant up to a total of 145,000 share-based instruments for the purpose of the company’s long-term incentive plan (LTIP) for the Board of Management and key employees for 2026. The objectives of the LTIP are to incentivise and reward lon...
EURneffy 1 mg approved across the EU as the first and only needle-free...
EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European Commission (EC) granted marketing authorisation for EURneffy® 1 mg – extending a class of treatment previously available only by injection. EURneffy® 1 mg is now indicated for the emergency treatment of anaphylaxis due to insect stings or bites, foods, me...
Generalforsamling i ALK-Abelló A/S afholdt den 16. marts 2026
Generalforsamling i ALK-Abelló A/S afholdt den 16. marts 2026 ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): ALK-Abelló A/S afholdt ordinær generalforsamling den 16. marts 2026. På generalforsamlingen skete følgende: Årsrapport 2025 blev godkendt, og der blev meddelt decharge for bestyrelse og direktion.Der blev truffet beslutning om at udbetale et ordinært udbytte på 1,6 kr. pr. aktie a en nominel værdi på 0,50 kr. til aktionærerne, svarende til et samlet udbytte på DKK 355 mio., og at det resterende nettooverskud på DKK 842 mio. blev overført til næste regnskabsår. Vederlagsrapporten for 2...
Annual General Meeting in ALK-Abelló A/S held on 16 March 2026
Annual General Meeting in ALK-Abelló A/S held on 16 March 2026 ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): ALK-Abelló A/S held its Annual General Meeting on 16 March 2026. The Annual General Meeting transacted the following business: Approval of the annual report 2025 and discharge of the Board of Directors and Board of Management.Resolution to declare that an ordinary dividend of DKK 1.6 per share of a nominal value of DKK 0.50, corresponding to a total dividend of DKK 355 million, was distributed to shareholders and that the remaining net profit of DKK 842 million was carried forward.Ado...
New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal a...
New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis, demonstrating that 88% of participants prefer EURneffy®—the first and only approved needle-free adrenaline-based product—over traditional adrenaline auto-injectors.i,ii The late-breaking data, presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA, United States, suggest EURneffy® has...
- ABGSC Healthcare Research
- Morten Larsen
Ordinær generalforsamling i ALK-Abelló A/S den 16. marts 2026
Ordinær generalforsamling i ALK-Abelló A/S den 16. marts 2026 Ordinær generalforsamling i ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) finder sted mandag den 16. marts 2026 kl. 16.00 hos ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm i henhold til vedhæftede indkaldelse med bestyrelsens fuldstændige forslag, som fremsættes på generalforsamlingen. ALK-Abelló A/S For yderligere oplysninger kontakt venligst:Investor Relations: Per Plotnikof, tlf. 4574 7527, mobil 2261 2525Presse: Maiken Riise Andersen, tlf. 5054 1434 Om ALKALK er en global, specialiseret medicinalvirksomhed med fok...
Annual General Meeting in ALK-Abelló A/S on 16 March 2026
Annual General Meeting in ALK-Abelló A/S on 16 March 2026 The Annual General Meeting of ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) will take place on Monday, 16 March 2026 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached. ALK-Abelló A/S For further information, contact: Investor Relations: Per Plotnikof, tel. , mobile Media: Maiken Riise Andersen, tel. About ALKALK is a global specialty pharmaceutical company focused on allergy. ALK's activiti...
- ABGSC Healthcare Research
- Morten Larsen
Henriette Mersebach fratræder som forskningsdirektør i ALK
Henriette Mersebach fratræder som forskningsdirektør i ALK ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) har i dag meddelt, at Henriette Mersebach fratræder som Executive Vice President, Research and Development, og som medlem af direktionen med virkning fra 23. februar 2026. Det er aftalt, at hun bistår med overlevering efter behov. Efter gensidig aftale har den administrerende direktør, bestyrelsen og Henriette Mersebach aftalt, at nu er det rette tidspunkt at udpege en ny forskningsdirektør med en anden profil for at styrke ALK’s innovationsindsats under Allergy+-strategien. Formålet er at b...
Henriette Mersebach to step down as ALK’s head of R&D
Henriette Mersebach to step down as ALK’s head of R&D ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Henriette Mersebach will step down as Executive Vice President, Research and Development, and as a member of the Board of Management, effective 23 February 2026. It has also been agreed that she will support the transition and assist with handover as needed. By mutual agreement, the CEO, Board of Directors and Henriette Mersebach have decided that it is the right time to appoint a new head of R&D with a different profile to advance ALK’s innovation efforts under the Allergy+ ...
Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margi...
Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin ALK’s (ALKB:DC / Nasdaq Copenhagen: ALK B) full-year results came in at the top end of the latest outlook, supported by solid performance in Q4 and continued commercial momentum. ALK expects sustained high organic revenue growth of 11-15% and higher earnings in 2026, with profitability at around 25%, in line with ALK’s long-term targets. The Board of Directors recommends dividend payments for 2025 of DKK 355 million, corresponding to approximately 30% of net profit after tax, to reward shareholders directly. Q4 2025 pe...
- ABGSC Healthcare Research
- Morten Larsen
Invitation til præsentation af ALK’s årsrapport for 2025 fredag den 20...
Invitation til præsentation af ALK’s årsrapport for 2025 fredag den 20. februar 2026 ALK (ALKB:DC / OMX: ALK B) offentliggør sin årsrapport for 2025 om morgenen fredag den 20. februar 2026. ALK afholder senere samme dag kl. 13.30 (CET) en præsentation for investorer og analytikere, hvor ledelsen kommenterer på resultat og forventninger samt besvarer spørgsmål. ALK vil være repræsenteret ved Peter Halling, Adm. direktør, Claus Steensen Sølje, Finansdirektør og Per Plotnikof, IR-chef. Live audio-webcast Mødet audiocastes live på , hvor genafspilning af præsentationen også vil vær...
Invitation to the presentation of ALK’s annual report 2025 on Friday, ...
Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026 ALK (ALKB:DC / OMX: ALK B) will publish its annual report for 2025 in the morning on Friday, 20 February 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio webcasted live and be availab...
ALK modtager anbefaling om godkendelse af EURneffy® 1 mg: En nålefri a...
ALK modtager anbefaling om godkendelse af EURneffy® 1 mg: En nålefri anafylaksibehandling til børn Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at Det Europæiske Lægemiddelagenturs komite for godkendelse af medicin til mennesker (Committee for Medicinal Products for Human Use, ‘CHMP’) har vedtaget at anbefale en godkendelse af adrenalinnæsesprayen EURneffy® 1 mg (varemærket for neffy® i EU) til akutbehandling af allergiske reaktioner (anafylaksi) forårsaget af insektstik eller -bid, fødevarer, medicinske produkter og andre allergener samt idiopatisk eller træningsinducer...
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free...
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Committee for Medicinal Products for Human Use (‘CHMP’) of the European Medicines Agency has adopted a positive opinion recommending the granting of the marketing authorisation for EURneffy® (the trade name for neffy® in the EU) to include a 1 mg nasal adrenaline spray for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as wel...
ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in...
ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco ALK (ALKB:DC / OMX: ALK B) today announced that the company’s president & CEO, Peter Halling, is scheduled to give a company presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, 15 January 2026, at 9.45 AM PST / 12.45 PM EST / 6.45 PM CET. Representatives of the company will be available for meetings at the conference. ALK-Abelló A/S For further information, please contact: Investor Relations: Per Plotnikof, tel. , mobile Media: Maiken Riise Andersen, tel....
ALK – Finanskalender for regnskabsåret 2026
ALK – Finanskalender for regnskabsåret 2026 Finanskalender 2026 for ALK (ALKB:DC / OMX: ALK B): 23. januar 2026: Stilleperiode20. februar 2026: Offentliggørelse af årsrapport 202516. marts 2026 kl. 16.00: Ordinær generalforsamling Indkomne forslag til dagsordenen for den ordinære generalforsamling, der er modtagetaf selskabet senest den 30. januar 2026, vil blive optaget på dagsordenen(kan fremsættes på ) 7. april 2026: Stilleperiode5. maj 2026: Delårsrapport 1. kvartal (Q1) 202623. juli 2026: ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.